CPB
49
2
HSY
53
2
TAP
50
2
TRV
48
2
AON
19
-2
BSX
69
-2
GPS
52
5
FOX
40
5
PFE
40
7
HBI
25
4
SJM
31
-3
FCX
52
-4
UAL
54
-10
JWN
67
7
KSS
34
6
DE
36
4
HOG
33
6
KMB
48
-2
CFG
44
18
PSA
35
-8
CPB
49
2
HSY
53
2
TAP
50
2
TRV
48
2
AON
19
-2
BSX
69
-2
GPS
52
5
FOX
40
5
PFE
40
7
HBI
25
4
SJM
31
-3
FCX
52
-4
UAL
54
-10
JWN
67
7
KSS
34
6
DE
36
4
HOG
33
6
KMB
48
-2
CFG
44
18
PSA
35
-8
Financhill
Back

Editas Medicine 10K Form

Sell
37

EDIT
Editas Medicine

Last Price:
5.75
Seasonality Move:
4.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EDIT News And Ratings

See the #1 stock for the next 7 days that we like better than EDIT

EDIT Financial Statistics

Sales & Book Value

Annual Sales: $78.12M
Cash Flow: $-23.55M
Price / Cash Flow: 0
Annual Sales: $4.27
Price / Book: 1.32

Profitability

EPS (TTM): -2.05000
Net Income (TTM): $-153.22M
Gross Margin: --
Return on Equity: -42.86%
Return on Assets: -30.35%

Editas Medicine Earnings Forecast

Key Editas Medicine Financial Ratios

  • The Research & Development expenses have been 227.40% of Revenue.
  • The Interest Expense is 5.47% of Operating Income.
  • The Net Earning history of EDIT is -196.13% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 4 years.

Editas Medicine Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: EDIT
CUSIP: 28106W
Website: editasmedicine.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.39
Quick Ratio: 5.27

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EDIT Technical Analysis vs Fundamental Analysis

Sell
37
Editas Medicine (EDIT) is a Sell

Is Editas Medicine a Buy or a Sell?

  • Editas Medicine stock is rated a Sell
    The current Editas Medicine [EDIT] share price is $5.62. The Score for EDIT is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.